OverviewSuggest Edit

Solid Biosciences is a biotech company singularly focused on developing treatments and cures for Duchenne Muscular Dystrophy (DMD). The Company combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. Solid's mission is to improve daily life for patients and attack the roots of DMD.
TypePublic
Founded2013
HQCambridge, US
Websitesolidbio.com
Employee Ratings5

Latest Updates

Employees (est.) (Feb 2019)60
Job Openings15
Share Price (May 2019)$6.1 (+5%)

Key People/Management at Solid BioSciences

Ilan Ganot

Ilan Ganot

Founder and CEO
Jennifer Ziolkowski

Jennifer Ziolkowski

CFO
Joel Schnieder

Joel Schnieder

CTO
Alvaro Amorrortu

Alvaro Amorrortu

COO
Jorge Quioz

Jorge Quioz

Chief Medical Officer
Carl Morris

Carl Morris

Chief Scientific Officer
Show more

Solid BioSciences Office Locations

Solid BioSciences has offices in Cambridge, New York and Greater London
Cambridge, US (HQ)
161 First St
New York, US
41 E 11th St
Greater London, GB
24 Eversholt St
Greater London, GB
Euston House 24 Eversholt St
Show all (4)

Solid BioSciences Financials and Metrics

Solid BioSciences Revenue

Market capitalization (21-May-2019)

215.6m

Closing stock price (21-May-2019)

6.1
Solid BioSciences's current market capitalization is $215.6 m.
Show all financial metrics

Solid BioSciences Online and Social Media Presence

Embed Graph

Solid BioSciences News and Updates

Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update

– Dosing of SGT-001 initiated in second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg/kg –

Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update

–Activities underway to commence dosing of second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg/kg of SGT-001– –Activities underway to commence dosing of second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg/kg of SGT-001–

Lifshitz & Miller LLP Announces Investigation of Bristow Group Inc., Helius Medical Technologies, Inc., Nordstrom Inc., PriceSmart, Inc., Ryanair Holdings plc, Solid Biosciences Inc., and Vanda Pharmaceuticals Inc.

NEW YORK, Feb. 20, 2019 /PRNewswire/ -- Bristow Group Inc. (BRS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the Company disclosing that it "did not have adequate monitoring control processes in place related to non-financial...

Solid Biosciences stock falls 73% after preliminary Phase 1/2 trial shows efficacy issues with drug

Shares of Solid Biosciences fell 73% in premarket trade Tuesday after the company said preliminary findings from a Phase 1/2 clinical trial of lead candidate SGT-001 found that patients with Duchenne muscular dystrophy (DMD) who were treated with the drug showed low levels of microdystrophin protei…

Gene Therapy Market Growth Analysis Till 2025: AveXis, Vineti, Solid Biosciences., Spark Therapeutics, Inc., CHIMERON BIO, RENOVA THERAPEUTICS

Global Gene Therapy Market Analysis to 2025 is a specialized and in-depth study of the gene therapy industry with a focus on the global market trend. Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

Solid BioSciences Blogs

Solid Biosciences to Present at the J.P. Morgan Healthcare Conference

Solid Biosciences to Present at the J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Ilan Ganot, Co-Founder, Chief Executive Officer and President of Solid Biosciences will present at the 37th Annual J.…

Solid Biosciences to Present at the Credit Suisse Healthcare Conference

Solid Biosciences to Present at the Credit Suisse Healthcare Conference CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018 at 2…

Solid Biosciences to Present at the Cell & Gene Meeting on the Mesa

Solid Biosciences to Present at the Cell & Gene Meeting on the MesaOctober 1, 2018 CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Cell & Gene Meeting on the Mesa on Wednesday, October 3, 2018 at …

Solid Joins the Global DMD Community in Recognizing World Duchenne Awareness Day

Solid Joins the Global DMD Community in Recognizing World Duchenne Awareness DaySeptember 7, 2018 The Solid Biosciences team was honored to join the Duchenne muscular dystrophy community in recognizing World Duchenne Awareness Day. Only together can we end this devastating disease. …

Henry (4), Los Angeles, CA

Henry (4), Los Angeles, CA On a wide residential street in Los Angeles, California, four-year-old Henry is standing ready at the front door, smiling coyly. Gregarious by nature, he immediately brings his new guests inside to his toy cars and a neon orange racetrack that spreads across the living roo…

Solid BioSciences Frequently Asked Questions

  • When was Solid BioSciences founded?

    Solid BioSciences was founded in 2013.

  • Who are Solid BioSciences key executives?

    Solid BioSciences's key executives are Ilan Ganot, Jennifer Ziolkowski and Joel Schnieder.

  • How many employees does Solid BioSciences have?

    Solid BioSciences has 60 employees.

  • Who are Solid BioSciences competitors?

    Competitors of Solid BioSciences include UniQure, CAMP4 Therapeutics and miRagen Therapeutics.

  • Where is Solid BioSciences headquarters?

    Solid BioSciences headquarters is located at 161 First St, Cambridge.

  • Where are Solid BioSciences offices?

    Solid BioSciences has offices in Cambridge, New York and Greater London.

  • How many offices does Solid BioSciences have?

    Solid BioSciences has 4 offices.